AFT Pharmaceuticals Limited (NZX:AFT) Annual Report 2022
The latest annual report of AFT Pharmaceuticals Limited (AFT) was published on 31 Mar 2022. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.
Key Statistics - AFT Annual Results
Amounts in NZD
AFT Income Statement 2022 Annual Report
As per the latest Income Statement of AFT, the Net revenue increased by $17.21M (15%) compared to the previous period. The operating income in 2022 increased by $9.68M (90%). The net income as per the annual report was 19.85M which increased by $12.07M (155%) compared to previous year.
Income Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Total Revenue | 130.31M | 113.11M |
| Gross Profit | 61.77M | 48.74M |
| Operating Income | 20.39M | 10.71M |
| Income Before Tax | 18.68M | 7.89M |
| Net Income | 19.85M | 7.78M |
Balance Sheet - AFT 2022 Annual Report
Read further: AFT Balance Sheet Detailed Analysis
The latest balance sheet from annual result of AFT Pharmaceuticals Limited showed the company increased the cash on balance sheet by $4.73M (147%). The Net tangible assets of AFT on the balance sheet were at 40.76M which is $19.76M (94%) more than previous annual report. The total stockholder equity also increased by $20.16M (55%) compared to previous reporting period.
Balance Sheet Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Cash | 7.94M | 3.21M |
| Total Assets | 121.76M | 105.13M |
| Long Term Debt | 33.2M | 33.2M |
| Total Liabilities | 65.02M | 68.54M |
| Total Shareholder Equity | 56.74M | 36.59M |
| Net Tangible Assets | 40.76M | 21M |
Cash Flow Statement - AFT 2022 Annual Report
The 2022 annual cash flow statement of AFT Pharmaceuticals Limited showed that the net income increased by $12.07M (155%) compared to previous reporting period. Also the capital expenditure of AFT decreased by $-236000 (-254%).
As of 2022, the total cash from investing activities was -5.58M and total cash from financing activities was -3.91M.
Cash Flow Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Net Income | 19.85M | 7.78M |
| Capital Expenditures | -329k | -93k |
| Dividends Paid | - | -188k |
| Total Cash From From Investing Activities | -5.58M | -6.23M |
| Total Cash From From Financing Activities | -3.91M | 2.52M |
AFT Pharmaceuticals Limited Annual Report History
Income Statement
Income Statement history of AFT Pharmaceuticals Limited (NZX:AFT)
| 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 | |
|---|---|---|---|---|
| Total Revenue | 130.31M | 113.11M | 105.6M | 85.13M |
| Cost Of Revenue | 68.54M | 64.36M | 57.33M | 44.4M |
| Gross Profit | 61.77M | 48.74M | 48.27M | 40.73M |
| Research Development | 3.62M | 1.97M | 1.97M | 914k |
| Selling General Administrative | 37.99M | 36.69M | 37.3M | 35.42M |
| Non Recurring | - | - | - | - |
| Other Operating Expenses | -225k | -626k | -535k | -2.24M |
| Total Operating Expenses | 109.92M | 102.4M | 94.09M | 78.49M |
| Operating Income | 20.39M | 10.71M | 11.5M | 6.64M |
| Total Other Income Expense Net | -1.7M | -2.82M | 1.38M | -8.9M |
| Ebit | 20.39M | 10.71M | 11.5M | 6.64M |
| Interest Expense | -2.44M | -3.44M | -6.96M | -5.39M |
| Income Before Tax | 18.68M | 7.89M | 12.88M | -2.26M |
| Income Tax Expense | -1.16M | 105k | 185k | 168k |
| Minority Interest | - | - | - | - |
| Net Income From Continuing Ops | 19.85M | 7.78M | 12.69M | -2.43M |
| Discontinued Operations | - | - | - | - |
| Extraordinary Items | - | - | - | - |
| Effect Of Accounting Charges | - | - | - | - |
| Other Items | - | - | - | - |
| Net Income | 19.85M | 7.78M | 12.69M | -2.43M |
| Net Income Applicable To Common Shares | 19.85M | 7.59M | 11.7M | -3.36M |
Balance Sheet Statement
Balance Sheet Statement history of AFT Pharmaceuticals Limited (NZX:AFT)
| 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 | |
|---|---|---|---|---|
| Cash | 7.94M | 3.21M | 6.12M | 6.92M |
| Net Receivables | 29.87M | 29.23M | 22.63M | 16.28M |
| Inventory | 33.5M | 33.65M | 22.73M | 25.16M |
| Other Current Assets | 100k | - | 514k | - |
| Total Current Assets | 77.54M | 67.9M | 55.34M | 51.26M |
| Property Plant Equipment | 3.36M | 3.79M | 4.03M | 357k |
| Intangible Assets | 15.99M | 15.59M | 15.46M | 2.91M |
| Other Assets | 24.87M | 17.86M | 12.23M | 6.03M |
| Deferred Long Term Asset Charges | 2.77M | 724k | 705k | 705k |
| Total Assets | 121.76M | 105.13M | 87.05M | 63.59M |
| Accounts Payable | 12.07M | 14.7M | 8.62M | 6.67M |
| Short Long Term Debt | 4M | 5.16M | 2M | 41.75M |
| Other Current Liab | 4.33M | 4M | 7.39M | 6.63M |
| Long Term Debt | 33.2M | 33.2M | 41.2M | - |
| Deferred Long Term Liab | 22.11M | 17.13M | 11.52M | 5.33M |
| Total Current Liabilities | 29.05M | 32.1M | 25.1M | 58.5M |
| Total Liab | 65.02M | 68.54M | 69.8M | 58.5M |
| Common Stock | 80.77M | 80.36M | 57.06M | 57.06M |
| Retained Earnings | -21.42M | -41.26M | -49.27M | -61.01M |
| Treasury Stock | -2.61M | -2.51M | -1.32M | -1.33M |
| Other Stockholder Equity | -2.61M | -2.51M | -1.32M | -1.33M |
| Total Stockholder Equity | 56.74M | 36.59M | 6.46M | -5.27M |
| Net Tangible Assets | 40.76M | 21M | -9M | -8.19M |
Cash Flow Statement
Cash Flow Statement history of AFT Pharmaceuticals Limited (NZX:AFT)
| 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 | |
|---|---|---|---|---|
| Net Income | 19.85M | 7.78M | 12.69M | -2.43M |
| Depreciation | 913k | 975k | 956k | 243k |
| Change To Netincome | 732k | 3.5M | 82k | 7.85M |
| Change To Account Receivables | -4.96M | -4.56M | -7.3M | -2.05M |
| Change To Liabilities | -2.66M | 3.84M | 5.88M | -1.88M |
| Change To Inventory | 154k | -10.92M | 2.42M | -746k |
| Total Cash From Operating Activities | 14.15M | 750k | 14.88M | 1.07M |
| Capital Expenditures | -329k | -93k | -92k | -140k |
| Total Cashflows From Investing Activities | -5.58M | -6.23M | -6.56M | -4.88M |
| Net Borrowings | -2.02M | -5.49M | -2.65M | 7.42M |
| Other Cashflows From Financing Activities | -2.19M | -4.19M | -5.9M | -3.56M |
| Total Cash From Financing Activities | -3.91M | 2.52M | -9.12M | 3.72M |
| Effect Of Exchange Rate | 78k | 49k | 5k | 240k |
| Change In Cash | 4.73M | -2.91M | -797k | 146k |
| Issuance Of Stock | 295k | 12.4M | 3k | 3k |
| Dividends Paid | - | -188k | -566k | -134k |